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a  b  s  t  r  a  c  t
The management strategy of adrenal metastases depends on different clinical situations.
Adrenal metastasectomy in selected patients with isolated adrenal metastases is considered
the treatment of choice, showing prolonged survival compared to chemotherapy alone.
More  recently, Stereotactic Body Radiation Therapy (SBRT) has emerged as an alternative
local ablative treatment modality although limited data are available on the use of SBRT
in  treating adrenal gland metastases. Preliminary results are, however, encouraging, espe-Keywords:
Adrenal gland
Metastases
cially in selected patients with oligometastatic disease. We  herewith review and discuss the
potential role of SBRT as a local ablative treatment modality for adrenal metastases.
©  2015 Greater Poland Cancer Centre. Published by Elsevier Sp. z o.o. All rights reserved.
contraindicated in lesions larger than 6 cm. Overall, theStereotactic Body Radiation Therapy
1.  Introduction
The adrenal gland is a common site for metastasis from
a variety of tumours.1 The incidence of these metastases
from autopsies is about 13–35%2,3 in patients with malig-
nant tumours. Lung, melanomas, breast, stomach and kidney
cancers and lymphomas most commonly metastasize to the
adrenal glands.4
The management strategy of adrenal metastases (AM)
varies depending on the different clinical situations and can
include palliative treatment, chemotherapy, surgery and local
ablative treatments.5,6 Historically, radiotherapy has been
used with palliative intent with good response rates reported,
especially in terms of pain relief (40–80%) defined as a reduc-
tion in the use of analgesics.7–9
∗ Corresponding author at: Università Campus Bio-Medico di Roma, Via
Tel.:  +39 06 225418011/39 06 22541420; fax: +39 06 22541433.
E-mail address: e.ippolito@unicampus.it (E. Ippolito).
http://dx.doi.org/10.1016/j.rpor.2015.05.009
1507-1367/© 2015 Greater Poland Cancer Centre. Published by Elsevier However, in patients with oligometastatic disease, defined
by the presence of one to five metastases,10 aggressive local
therapies may be a reasonable option to prolong progression-
free survival.
Several studies have showed prolonged survival after
an adrenal metastasectomy in selected patients with iso-
lated adrenal metastases.11,12 Surgery can be performed
with an open resection or through laparoscopic approach.
Laparoscopic adrenalectomy has been shown to improve
patients’ morbidity and to reduce hospitalization with a
comparative oncological outcome compared to the open
resection technique.13 However, laparoscopic procedures are
14 Álvaro del Portillo 21, 00128 Rome, Italy.
rate of major complication after surgery is around 1.8%.15
Recently, Gunjar et al. in a systematic review reported a
weighted 2y OS for patients undergoing adrenalectomy for
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drenal gland metastases of 46%, representing a total of 655
atients.16
Other recently emerged treatment modalities include
adiofrequency Ablation (RFA), Microwave Ablation (MWA)
nd Stereotactic Body Radiation Therapy (SBRT).17
Limited data are available on the Percutaneous Catheter
blation Technique due to a limited number of patients. The
ost common histology treated with this modality is renal
ell carcinoma, where reported toxicity included hypertensive
risis and retroperitoneal haematoma.16
SBRT refers to the administration of large doses of highly
onformal radiation with steep dose gradients towards the
urrounding normal tissue over a limited number of fractions.
BRT usually provides much higher Biologically Equivalent
oses (BED) compared with conventional treatments and has
een used as a non-invasive alternative to the gold standard
f surgery in selected patients.18,19
Even though the majority of studies examining the role of
BRT have focused on lung and liver metastases, over the last
ears there has been an increasing interest in the use of SBRT
or the treatment of adrenal gland metastases.
Consequently, the main objective of this review is to exam-
ne available clinical data supporting the potential role of SBRT
n treating adrenal glands metastases and to outline inherent
uture challenges.
.  Materials  and  methods
 medline word search of literature undertaken for the period
rom 1 December 1994 to 30 November 2014, using the
earch terms “adrenal gland metastases” and “stereotactic
ody radiotherapy” was used. Reviews and case reports were
xcluded.
.  SBRT  for  adrenal  glands  metastases:
linical  data  overview
he review includes ten studies, of which nine were retrospec-
ive with the number of patients ranging from 7 to 48; all the
tudies were mono-institutional; the most common primary
ite of disease was lung cancer (44.4–100%); and in all stud-
es chemotherapy was not given concurrently with SBRT. Data
erived from these studies are summarized in Table 1.
.1.  Dose  and  fractionation
 large heterogeneity in total dose and fractionation
as observed. Radiosurgery (SRS) was employed in
nly two studies,20,21 with a median dose of 16–23 Gy
BED = 41.6–75.9 Gy, ˛/  ̌ = 10). Most patients had fractionated
BRT with a total dose range of 25–48 Gy delivered in fractions
f 3–18 (BED = 22.4–132, ˛/  ̌ = 10), with a total number of 5
ractions (4/10, 40%) administered most commonly, followed
y 3 fractions (3/10, 30%)..2.  Pain  relief
our studies20,22–24 evaluated pain control after SBRT in a
otal of 16 patients. A complete response to pain, followingtherapy 2 0 ( 2 0 1 5 ) 484–490 485
analgesic consumption interruption, was achieved in 12
patients (75%), notwithstanding the dose administered. In 2
patients (12.5%), a partial response was achieved (overall pain
response 87.5%). No information on the duration of pain relief
was provided.
3.3.  Efficacy
Overall, the 1- and 2-year local control (LC) rate ranged from
44 to 100% and from 27 to 100%, respectively. However, in most
of the studies (6/10, 60%), both 1 and 2 year local control was
greater than 70%. It should be noted that in the four studies
which showed a lower rate of local control, the median biolog-
ically equivalent dose delivered was lower than 60 Gy.21,22,25,26
In contrast, studies delivering higher biologically equiv-
alent doses (BED median > 85 Gy, BED maximum value
132–137 Gy, ˛/  ̌ = 10)20,27,28 reported a 2-year local con-
trol ≥ 90%. These data are consistent with that indicating that
a BED greater or equal to 100 Gy is necessary to control primary
NSCLC.29,30
One- and 2-year overall survival (OS) rate ranged from 39.7
to 90% and 13 to 53%, respectively, and was largely influenced
by the development of widespread distant metastases. How-
ever, the selection of patients seemed to have a strong impact
on these data, especially with regard to the type of metas-
tasis (isolated vs. not isolated), the state of oligometastatic
disease as defined by Hellman and Weichselbaum10 and the
time of onset of the adrenal metastasis (synchronous vs.
metachronous).
In effect, in the study by Holy et al.24 patients with soli-
tary metastasis (72.2%) had a median PFS of 12 months and
a median OS of 23 months, comparable to some of the sur-
gical series.31 Furthermore, in the study conducted by Rudra
et al.,32 which included only patients with oligometastatic
disease, the reported 1 year OS was 90% with a median
survival of 17.3 months. Finally, in the study by Oshiro et
al.,27 patients with metachronous metastasis (with a disease
free-interval > 6 months), when compared to the whole study
population, showed an improved 2-year OS of 55.6% with
median survival of 44.3 months.
3.4.  Toxicity
In all the studies, toxicity was limited with no report of
grade ≥ 3. The most commonly reported acute toxicity was
nausea and fatigue G1–G2 with an overall incidence of 30–50%.
Among all the studies, 3 gastro-intestinal (GI) ulcers (1 duo-
denal, 1 gastric, 1 both duodenal and gastric) were reported,
and were all treated successfully with a histamine-2 receptor
antagonist. Particularly in the series by Oshiro et al.27, patients
who developed duodenal ulcer received 30 Gy in 3 fractions
(BED 60 Gy, ˛/  ̌ = 10) with a maximum dose of 30 Gy at the duo-
denum (BED 130 Gy, ˛/  ̌ = 3). In contrast, in the series by Holy
et al.24 patients who were developing ulcers were treated with
a BED of 72 Gy (˛/  ̌ = 10), but the corresponding dose–volume
load to the stomach and the small intestine was below the
tolerance level of these organs. The authors concluded that
there might have been some uncertainties in dose–volume
load because patients were not treated on an empty stomach,




































Table 1 – SBRT for adrenal glands: clinical data.
Author Patients Primary Volumes Technique Prescription Dose
(median/
range)
N◦fractions BED 10 Response
(evaluable pts)
























1 y – 100%
2  y - 100%


























1 y – 55%
2  y – 27%
1 y – 44%
2  y – 25%
5–21
months
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2 y – 32%
1 y 64.8%



















































































1 y – 73%
2  y – 73%






































































1 y – 90%
2  y – 90%
1  y  –  39.7%






























































1y –  55.6%




GI = gastrointestinal; GTV = gross tumour volume; CTV = clinical target volume; ITV = internal target volume; PTV = Planning Target Volume; RTRT =  Real Time Tumour Tracking; BED10 = Biologically
equivalent dose, ˛/ˇ = 10; SRS = Radiosurgery.
Table 2 – Constraints used for different SBRT schedules.
Author No. fractions Stomach/duodenum Ipsilateral kidney Bilateral kidney Small bowel Spinal cord
Katoh 200823 8 1cc < 35 Gy V20 Gy ≤ 50% NA NA NA
Casamassima 201020 3 V25 < 5% V15 Gy < 50% V15 < 35% V27 < 2%
Ahmed 201328 5 Dmax < 42 Gy
V38 < 5 cc
V32.5 < 15 cc
V20 < 30 cc
NA NA Dmax < 42 Gy
V38 < 5 cc
V32.5 < 15 cc
V20 < 30 cc
Dmax < 30 Gy
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Recently, Onishi et al.33 reported a clinical case of fatal
gastric ulcer occurring 5.5 months after receiving SBRT for a
left adrenal metastasis. SBRT was delivered concurrently with
vinorelbine (25 mg/m2 days 1–8 every 3 weeks) and a daily CT
scan was performed to verify the position of the gastric wall;
the patient was treated with a total dose of 60 Gy delivered in
10 fractions (BED 96 Gy, ˛/  ̌ = 10) with a very high maximum
dose to the gastric wall of 61 Gy (BED 185 Gy, ˛/  ̌ = 3).
Adrenal insufficiency can be caused by the tumour itself, as
well as by local treatment. Despite high incidences of adrenal
metastases in all malignancies, the incidence of symptomatic
adrenal insufficiency remains low (4%),34,35 which can be
explained by the fact that over 90% of adrenal reserve must
be destroyed before it becomes dysfunctional.
Among all the studies, two grade 2 adrenal insufficiencies
were reported,20,33 but no details were provided regarding the
doses received by these patients, nor was it specified whether
adrenal function was assessed before treatment. Recently, a
clinical case of adrenal insufficiency after SBRT for bilateral
adrenal metastases36 was reported.
Constraints used in the studies for different fraction num-
ber are summarized in Table 2.
3.5.  Technical  issues
All patients underwent CT-based treatment planning in
custom-made immobilization devices. Katoh et al.23 inves-
tigated three-dimensional tumour motion of the fiducial
marker inserted in the adrenal metastasis resulting in a large
marker shift related to organ movement, greater in the cranio-
caudal direction (1 cm). There was no statistically significant
difference in the average amplitude between the supine and
prone positions along the three axes, as well as with regard
to the distance between the stomach, the duodenum and
the tumour. For this reason, the authors recommended the
supine treatment which is more  reliable and comfortable for
patients.
In order to manage target motion, either breath holding
techniques or 4D CT scans or simulation CT scans in both
inspiration and expiration phases were performed in almost
all studies. Advanced IGRT devices were used in half of the
studies during treatment, allowing smaller PTV margins.
3D treatment planning was used in almost all studies; how-
ever, Scorsetti et al.37 in a previous report found intensity
modulated techniques using either static fields or dynamic
arcs and proton therapy superior to conformal solutions,
thereby suggesting their use to increase the total dose admin-
istered.
4.  Conclusions  and  future  directions
As current studies available on treatment of adrenal metas-
tases are few and extremely heterogeneous in terms of patient
selection (primary tumours, previous treatment, performance
status, disease extension), as well as with regard to dose and
fractionation schedules used, the optimal SBRT regimen is yet
to be determined and no comparative studies can be under-
taken with other treatment options.iotherapy 2 0 ( 2 0 1 5 ) 484–490
Overall, the reported toxicity rate was extremely low, but
as all the studies were retrospective and the median follow-
up time was limited, this could possibly cause the SBRT
related side effects to be underestimated. An accurate base-
line evaluation of patients’ history should be undertaken prior
to treatment, as some studies have shown that a history of
gastro-duodenal ulcer is a significant risk factor for ulcera-
tion after conventional RT38 and SBRT39 and recommend that
these patients be treated with considerable caution. Moreover,
some clinical conditions such as portal hypertension cause
functional abnormalities in the gastric mucosa and reduce
the defensive and healing mechanism,40 thus leading to an
increased risk of gastrointestinal toxicity.
In the studies reviewed, GI toxicity occurred when the
maximum biologically equivalent dose to the duodenum or
gastric wall was ≥130 (˛/  ̌ = 3) and we therefore suggest that
the maximum dose to either the gastric wall or duodenum be
kept below this value, regardless of the number of fractions
used.
Furthermore, adrenal function should be assessed before
and after SBRT in order to provide glucocorticoids and miner-
alocorticoids replacement when needed, and careful attention
should be paid when bilateral SBRT is administered as acute
adrenal crisis requires urgent hospitalization as it is managed
with intravenous fluids and steroid replacement.
Simulation and treatment should be performed on an
empty stomach in order to reduce uncertainties regarding
organ filling. Furthermore, due to adrenal gland organ motion,
IGRT is also strongly recommended, when available. Treat-
ment modalities such as IMRT/VMAT can be used in a dose
escalation treatment protocol, leading to improved organ spar-
ing compared with 3D techniques.37
Efficacy results also appear promising. An encouraging 2-
year local control rate (>70%) can be achieved with different
fractionation schemes (3, 5, 8 fractions) if total BED is greater
than 60 Gy. An even higher local control rate (>90%) can be
achieved using total BED ≥ 90 Gy. Based on the above consid-
erations, we recommend that a total dose corresponding to a
BED ≥ 90 Gy be administered, bearing in mind that a lower dose
(minimum BED ≥ 60 Gy) might be considered if dose volume
constraints are not satisfied.
For effective research to ascertain whether local control
improvement can lead to extended progression-free survival
or overall survival, patients included in SBRT studies should
be carefully selected.
Moreover, patients selected for ablative SBRT should have
a better prognosis, similar to those enrolled in surgical stud-
ies. Patients meeting these criteria are those with isolated
metastases or oligometastatic disease (≤5 lesions, metastatic
disease confined in ≤2 organs) and a prolonged disease-free
interval (>6 months).
In conclusion, SBRT has shown promising results in
selected patients with limited toxicity. For this reason, it can
be considered an effective alternative for patients not eligible
for surgical resection, although prospective clinical trials are
necessary to establish the optimal SBRT regimen and to better
define the role of SBRT compared to surgery and other local
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